Table 4 Ongoing clinical trials to target Tregs in cancer patients
From: Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Target | Agent | Tumor types and combinational therapies | Phase | Sample size | Clinical trial number |
|---|---|---|---|---|---|
Anti-CD25 antibody | Daclizumab | Melanoma | I/II | 15 | NCT00847106 |
Basiliximab | Glioblastoma Multiforme | I | 34 | NCT00626483 | |
Anti- CCR4 antibody | Mogamulizumab (KW-0761) | Advanced Solid Tumors + Nivolumab | I | 118 | NCT02476123 |
CCR4 inhibitor | FLX475 | Advanced Cancer + Pembrolizumab | I/II | 375 | NCT03674567 |
Gastric Cancer + Pembrolizumab | II | 90 | NCT04768686 | ||
Anti-CTLA-4 antibody | Tremelimumab | Metastatic Urothelial Cancer | II | 28 | NCT03557918 |
NSCLC + Durvalumab | II | 15 | NCT04625699 | ||
Ovarian Cancer | I/II | 50 | NCT02571725 | ||
NSCLC + Durvalumab | I | 31 | NCT03275597 | ||
Ipilimumab | Hepatocellular Carcinoma + Nivolumab | II | 40 | NCT03510871 | |
NSCLC + Nivolumab | II | 50 | NCT03262779 | ||
Renal Cell Carcinoma + Nivolumab | II | 74 | NCT03297593 | ||
Advanced Melanoma + FLX475 | II | 20 | NCT0489499 | ||
Anti-GITR agonistic antibody | BMS-986156 | Solid Tumors | I/II | 60 | NCT04021043 |
GWN323 | Solid Tumors + PDR001 | I | 92 | NCT02740270 | |
INCAGN0187 | Glioblastoma + INCAGN01876 + Stereotactic Radiosurgery | II | 32 | NCT04225039 | |
REGN6569 | Squamous Cell Carcinoma of Head and Neck + Cemiplimab | I | 85 | NCT04465487 | |
ASP1951 | Advanced Solid Tumors + Pembrolizumab | I | 436 | NCT03799003 | |
Anti-LAG-3 antibody | BMS 986,016 (Relatlimab) | Glioblastoma | I | 63 | NCT02658981 |
Sym022 | Solid Tumor | I | 15 | NCT03489369 | |
REGN3767 | Malignancies | I | 669 | NCT03005782 | |
INCAGN02385 | Melanoma + INCMGA00012 (anti-PD-1) + INCAGN02390 (anti-TIM-3) | I/II | 52 | NCT04370704 | |
Anti-LAG-3/PD-L1 antibody | IBI323 | Advanced Malignancies | I | 322 | NCT04916119 |
MGD013 | Advanced Solid Tumors | I | 353 | NCT03219268 | |
RO7247669 | Solid Tumors | I | 320 | NCT04140500 | |
Anti-TIGIT antibody | Ociperlimab (BGB-A1217) | Cervical Cancer + Tislelizumab | II | 167 | NCT04693234 |
AB154 | Glioblastoma + AB122 | I | 46 | NCT04656535 | |
Tiragolumab | NSCLC + Atezolizumab | III | 560 | NCT04294810 | |
IBI939 | NSCLC | I | 42 | NCT04672369 | |
Anti-TIGIT/PD-1 antibody | AZD2936 | NSCLC | I/II | 147 | NCT04995523 |
Anti-OX40 antibody | PF-04518600 | Metastatic Renal Cell Carcinoma + Axitinib | II | 104 | NCT03092856 |
MEDI6469 | Colorectal Neoplasms | I | 4 | NCT02559024 | |
BMS 986,178 | Solid Tumors | I | 12 | NCT03831295 | |
INCAGN01949 | Stage IV Pancreatic and Other Cancers Except Melanoma + CMP-001 | I/II | 42 | NCT04387071 | |
Anti-ICOS antibody | KY1044 | Advanced Cancer + Atezolizumab | I/II | 412 | NCT03829501 |
Feladilimab | Head and Neck Squamous Cell Carcinoma + Pembrolizumab | II/III | 314 | NCT04128696 |